Indian Pazopanib Exporters: Complete Supplier Ranking with Market Share — 196 Manufacturers (2026) — TransData Nexus

Q: Who is the largest pazopanib buyer importing from India?

SUN PHARMACEUTICAL INDUSTRIES INC (UNITED STATES) is the largest pazopanib importer from India with a 39.5% market share and import value of $3.3M.

Q: How many pazopanib buyers import from India?

There are 196 active pazopanib buyers importing from India, with a combined import market of $8.3M across 498 shipments according to Indian Customs (DGFT) records.

Q: What is the market share of top pazopanib buyers from India?

The top 5 pazopanib buyers — SUN PHARMACEUTICAL INDUSTRIES INC, SUN PHARMACEUTICAL INDUSTRIES,INC., M/S.NOVUGEN ONCOLOGY SDN.BHD, LOTUS PHARMACEUTICAL CO.LTD.,, STATE PHARMACEUTICALS CORPORATION — together control 86.2% of total pazopanib import value from India.

Suresh Sormare

Pazopanib

India Pharmaceutical Trade Intelligence

$8.3M109 Suppliers57 CountriesHS 30049049

ExportsIndia → UNITED STATES84.4%India → GEORGIA2.6%

ImportsUNITED KINGDOM → India$3.3M SWITZERLAND → India$596.6K

#1 Supplier: SUN PHARMACEUTICAL #1 Buyer: SUN PHARMACEUTICAL

Market Analysis: Top Importing Countries & Their Importers

1United States

United States emerges as the first largest importing country, achieving a total trade value of $7.0M through 15 shipments. This represents a market share of 84.4% of the total market activity, demonstrating their significant presence in the industry.

Top Importers: United States has a diverse importer base, with their top importers including:

• SUN PHARMACEUTICAL INDUSTRIES INC - $3.3M (46.8% of country's total business)

• SUN PHARMACEUTICAL INDUSTRIES,INC. - $3.3M (46.3% of country's total business)

• M/S.NOVUGEN ONCOLOGY SDN.BHD - $282.3K (4.0% of country's total business)

Key Insight: United States demonstrates strong market positioning with an average shipment value of $470.0K, indicating premium pricing strategy compared to the market average of $16.8K.

United States is a key market for Pazopanib imports, representing 84.4% of total trade value.

Primary Market

Secondary Market

2Georgia

Georgia emerges as the second largest importing country, achieving a total trade value of through . This represents a market share of of the total market activity, demonstrating their significant presence in the industry.

Buyer Segment Analysis

TransData Nexus Pazopanib buyer market intelligence

1Buyer Segment Analysis

Our analysis of Pazopanib imports from India between 2022 and 2026 reveals a diverse buyer landscape, encompassing various segments:

Pharmaceutical Manufacturers: SUN PHARMACEUTICAL INDUSTRIES INC and SUN PHARMACEUTICAL INDUSTRIES, INC., both based in the United States, are prominent buyers, accounting for a combined $6.57 million in imports. These entities likely procure Pazopanib for further processing, packaging, or distribution under their brand names. Their substantial purchase volumes suggest a consistent demand, possibly linked to their market presence and distribution networks.

Government Procurement Agencies: STATE PHARMACEUTICALS CORPORATION in Sri Lanka imported $0.16 million worth of Pazopanib. As a government entity, it likely acquires medications to supply public healthcare facilities, ensuring access to essential medicines for the population. Such agencies typically engage in bulk purchasing through tenders, aiming for cost-effective procurement to support national health programs.

Distributors and Trading Companies: Entities like TISHAS ADDITIONAL LIABILITY COMPANY (Belarus, $0.15 million), STR INTERNATIONAL TRADING CO., LTD (Thailand, $0.05 million), and MERMISI LLC (Georgia, $0.03 million) function as intermediaries, supplying Pazopanib to local pharmacies, hospitals, or other end-users. Their purchasing patterns may vary based on market demand, regulatory approvals, and existing supply agreements.

Country-Specific Import Regulations

TransData Nexus Pazopanib buyer market intelligence

1Country-Specific Import Regulations

United States

1. Regulatory Authority: U.S. Food and Drug Administration (FDA)

2. Import Registration Process: Importers must ensure that Pazopanib is FDA-approved. The process involves submitting an Abbreviated New Drug Application (ANDA) for generic drugs or a New Drug Application (NDA) for new drugs.

3. Estimated Timeline: The FDA review process typically takes 10 months for standard applications, but it can be expedited under certain conditions.

4. Import Tariff/Duty: Pharmaceutical products under HS Code 30049049 are generally duty-free in the United States.

Georgia

1. Regulatory Authority: Ministry of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs of Georgia

2. Import Registration Process: Importers must register Pazopanib with the Ministry, providing documentation on quality, safety, and efficacy.

3. Estimated Timeline: The registration process can take approximately 6 to 12 months, depending on the completeness of the application and any additional requirements.

4. Import Tariff/Duty: Pharmaceutical products under HS Code 30049049 are subject to a 5% import duty in Georgia.

Taiwan

1. Regulatory Authority: Taiwan Food and Drug Administration (TFDA)

2. Import Registration Process: Importers must submit a registration dossier to the TFDA, including clinical data, manufacturing details, and labeling information.

3. Estimated Timeline: The registration process typically takes 12 to 18 months, depending on the complexity of the application and any required inspections.

4. Import Tariff/Duty: Pharmaceutical products under HS Code 30049049 are generally exempt from import duties in Taiwan.

Demand Drivers & Market Opportunity

TransData Nexus Pazopanib buyer market intelligence

1Demand Drivers & Market Opportunity

The demand for Pazopanib, an angiogenesis inhibitor used primarily in the treatment of advanced renal cell carcinoma and soft tissue sarcoma, is influenced by several factors:

1. Disease Prevalence: The global incidence of renal cell carcinoma has been rising, with the World Health Organization reporting approximately 431,000 new cases in 2022. This increasing prevalence directly correlates with the demand for effective treatments like Pazopanib.

2. Government Healthcare Programs: Many countries have implemented national cancer control programs aimed at improving access to oncology treatments. For instance, the United States' Cancer Moonshot initiative, launched in 2022, focuses on accelerating cancer research and improving patient access to therapies.

3. Universal Health Coverage Expansion: Countries like Sri Lanka and Belarus have been expanding their universal health coverage, ensuring that a larger segment of the population has access to essential medicines, including oncology drugs.

4. WHO Essential Medicines List Procurement: Pazopanib's inclusion in the WHO Model List of Essential Medicines facilitates its procurement by various countries, especially those relying on the list to guide their national formularies.

5. Tender-Based Purchasing: Government procurement agencies, such as Sri Lanka's State Pharmaceuticals Corporation, often engage in tender-based purchasing to acquire medications like Pazopanib in bulk, ensuring cost-effectiveness and consistent supply for public healthcare facilities.

Our data indicates that between 2022 and 2026, 196 buyers across 57 countries imported Pazopanib from India, reflecting a broad and growing market. The repeat buyer rate of 46.9% suggests sustained demand, likely driven by the factors mentioned above.

Common Questions — Pazopanib Buyers & Importers

Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus

QWho is the largest pazopanib buyer importing from India?

Based on import volume and value, SUN PHARMACEUTICAL INDUSTRIES INC (UNITED STATES) leads with $3.3M in imports and a 39.5% market share — the highest of any single pazopanib importer. SUN PHARMACEUTICAL INDUSTRIES,INC. (UNITED STATES) and M/S.NOVUGEN ONCOLOGY SDN.BHD (UNITED STATES) are the next largest buyers.

QHow many companies buy pazopanib from India?

There are 196 active pazopanib buyers importing from India, with a combined market of $8.3M across 498 shipments to 57 countries. The top 5 buyers hold 86.2% of total import value, while the remaining 191 buyers handle the other 13.8%.

QWhich countries import the most pazopanib from India?

The top importing countries for pazopanib from India are United States (84.4%), Georgia (2.6%), Taiwan (2.3%), Sri Lanka (1.9%), Belarus (1.8%). These markets represent the largest demand centres for Indian pharmaceutical exports of pazopanib, with buyers ranging from government procurement agencies to private pharmaceutical distributors.

Buyer Segment Analysis

TransData Nexus Pazopanib buyer market intelligence

1Buyer Segment Analysis

Our analysis of Pazopanib imports from India between 2022 and 2026 reveals a diverse buyer landscape, encompassing various segments:

Pharmaceutical Manufacturers: SUN PHARMACEUTICAL INDUSTRIES INC and SUN PHARMACEUTICAL INDUSTRIES, INC., both based in the United States, are prominent buyers, accounting for a combined $6.57 million in imports. These entities likely procure Pazopanib for further processing, packaging, or distribution under their brand names. Their substantial purchase volumes suggest a consistent demand, possibly linked to their market presence and distribution networks.

Government Procurement Agencies: STATE PHARMACEUTICALS CORPORATION in Sri Lanka imported $0.16 million worth of Pazopanib. As a government entity, it likely acquires medications to supply public healthcare facilities, ensuring access to essential medicines for the population. Such agencies typically engage in bulk purchasing through tenders, aiming for cost-effective procurement to support national health programs.

Distributors and Trading Companies: Entities like TISHAS ADDITIONAL LIABILITY COMPANY (Belarus, $0.15 million), STR INTERNATIONAL TRADING CO., LTD (Thailand, $0.05 million), and MERMISI LLC (Georgia, $0.03 million) function as intermediaries, supplying Pazopanib to local pharmacies, hospitals, or other end-users. Their purchasing patterns may vary based on market demand, regulatory approvals, and existing supply agreements.

Country-Specific Import Regulations

TransData Nexus Pazopanib buyer market intelligence

1Country-Specific Import Regulations

United States

1. Regulatory Authority: U.S. Food and Drug Administration (FDA)

3. Estimated Timeline: The FDA review process typically takes 10 months for standard applications, but it can be expedited under certain conditions.

4. Import Tariff/Duty: Pharmaceutical products under HS Code 30049049 are generally duty-free in the United States.

Georgia

1. Regulatory Authority: Ministry of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs of Georgia

2. Import Registration Process: Importers must register Pazopanib with the Ministry, providing documentation on quality, safety, and efficacy.

3. Estimated Timeline: The registration process can take approximately 6 to 12 months, depending on the completeness of the application and any additional requirements.

4. Import Tariff/Duty: Pharmaceutical products under HS Code 30049049 are subject to a 5% import duty in Georgia.

Taiwan

1. Regulatory Authority: Taiwan Food and Drug Administration (TFDA)

2. Import Registration Process: Importers must submit a registration dossier to the TFDA, including clinical data, manufacturing details, and labeling information.

3. Estimated Timeline: The registration process typically takes 12 to 18 months, depending on the complexity of the application and any required inspections.

4. Import Tariff/Duty: Pharmaceutical products under HS Code 30049049 are generally exempt from import duties in Taiwan.

Demand Drivers & Market Opportunity

TransData Nexus Pazopanib buyer market intelligence

1Demand Drivers & Market Opportunity

The demand for Pazopanib, an angiogenesis inhibitor used primarily in the treatment of advanced renal cell carcinoma and soft tissue sarcoma, is influenced by several factors:

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Pazopanib

Pazopanib

Who Buys Pazopanib from India — 196 Importers Behind a $8.3M Market

Top Pazopanib Importers — Ranked by Import Value

Top Pazopanib Buyers & Importers

Related Analysis

Need Details?

Market Analysis: Top Importing Countries & Importers

Which companies are buying Pazopanib — and from which countries?

Pazopanib — Buyer Countries to Key Importers

Market Analysis: Top Importing Countries & Their Importers

1United States

2Georgia

Buyer Segment Analysis

1Buyer Segment Analysis

Country-Specific Import Regulations

1Country-Specific Import Regulations

Demand Drivers & Market Opportunity

1Demand Drivers & Market Opportunity

Common Questions — Pazopanib Buyers & Importers

QWho is the largest pazopanib buyer importing from India?

QHow many companies buy pazopanib from India?

QWhich countries import the most pazopanib from India?

Buyer Segment Analysis

1Buyer Segment Analysis

Country-Specific Import Regulations

1Country-Specific Import Regulations

Demand Drivers & Market Opportunity

1Demand Drivers & Market Opportunity

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

3Taiwan

4Sri Lanka

5Belarus

QWhat is the average import order value for pazopanib from India?

Analysis Methodology